Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarcellin, P.-
dc.contributor.authorDe Bony, F.-
dc.contributor.authorGarret, C.-
dc.contributor.authorAltman, C.-
dc.contributor.authorBoige, V.-
dc.contributor.authorCastelnau, C.-
dc.contributor.authorLaurent-Puig, P.-
dc.contributor.authorTrinchet, J.-
dc.contributor.authorRolan, P.-
dc.contributor.authorChen, C.-
dc.contributor.authorMamet, J.-
dc.contributor.authorBidault, R.-
dc.identifier.citationBritish Journal of Clinical Pharmacology, 2001; 51(5):410-414-
dc.description.abstractAIMS: Lamotrigine, an antiepileptic drug, is cleared from the systemic circulation mainly by glucuronidation. The possibility of changes in the pharmacokinetics of lamotrigine in plasma owing to hepatic dysfunction has been evaluated. METHODS: Thirty-six subjects, including 24 patients with various degrees of liver cirrhosis and 12 healthy volunteers received a single 100 mg dose of lamotrgine. Blood samples were taken for 7 days in all subjects, except nine with severe cirrhosis, who had a 29 day blood sampling period. RESULTS: The pharmacokinetics of lamotrigine were comparable between the patients with moderate cirrhosis (corresponding to Child-Pugh grade A) and the healthy subjects. Plasma oral clearance mean ratios (90% confidence interval) in patients with severe cirrhosis without or with ascites (corresponding, respectively, to Child-Pugh grade B and C) to healthy subjects were, respectively, 60% (44%, 83%) and 36% (25%, 52%). Plasma half-life mean ratios (90% confidence interval) in these two patient groups to healthy subjects were, respectively, 204% (149%, 278%) and 287% (202%, 408%). CONCLUSIONS: Lamotrigine administered as a single oral dose of 100 mg was well tolerated in all groups. Initial, escalation and maintenance doses should generally be reduced by approximately 50 or 75% in patients with Child-Pugh Grade B or C cirrhosis. Escalation and maintenance doses should be adjusted according to clinical response.-
dc.description.statementofresponsibilityP. Marcellin, F. De Bony, C. Garret, C. Altman, V. Boige, C. Castelnau, P. Laurent-Puig, J. C. Trinchet, P. Rolan, C. Chen, J. P. Mamet, R. Bidault-
dc.publisherBlackwell Publishing Ltd-
dc.titleInfluence of cirrhosis on lamotrigine pharmacokinetics-
dc.typeJournal article-
Appears in Collections:Aurora harvest 6
Pharmacology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.